|
Orthologous residues
|
|
BRCA2 (human): S3291‑p, BRCA2 (mouse): S3214‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Disease tissue studied:
fibrosarcoma of soft tissue
|
|
Relevant cell lines - cell types - tissues:
HeLa (cervical), HT1080 (fibroblast)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
nocodazole
|
|
|
|
increase
|
|
|
ionizing radiation
|
|
|
|
decrease
|
|
|
|
ionizing radiation
|
ATM (human)
|
|
inhibit treatment-induced decrease
|
deficient cells
|
|
roscovitine
|
|
|
|
decrease
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation
|
|
Effect of modification (process):
cell cycle regulation
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
Rad51 (human)
|
|
Disrupts
|
|
|
pull-down assay
|
|
|
Comments:
double-strand break repair efficiency
|
|
Associated Diseases
|
|
Diseases:
|
Alterations:
|
Comments:
|
|
breast cancer
|
mutation of site
|
|
|
